NCT07413757Recruiting
CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC
A Cross-sectional Survey-based Study Using Preference Elicitation Method to Assess Decision-making Impact Factor of Chinese Patients and Physicians for First-line EGFR-TKIs Treatment of Stage IV NSCLC (CHOICE)
Source: ClinicalTrials.gov · Last updated 9 Oct 2026
Brief summary (registry, in English)
This non-interventional, cross-sectional study aims to investigate treatment preferences from a sample of physicians and patients with experience of 1L EGFR-TKI for stage IV NSCLC by administering a survey, which primarily includes a DCE approach.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 590 (estimated)
- First submitted
- 9 Feb 2026
- Start date
- 2 Mar 2026
- Primary completion date
- 12 Nov 2026
- Lead sponsor
- AstraZeneca
- Diseases
- Lung cancer
- NCT number
- NCT07413757
What you commit to
- Study type: Observational
- Planned participants: 590
- From 2 Mar 2026 to the primary completion date, 12 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Not applicable.
Who the study is looking for
- The following inclusion criteria must be met in order to be enrolled in the stage 1:
- Patient:
- Provide informed consent
- 18 years or older
- Diagnosed with stage IV NSCLC
- Currently receiving or previously received 1L EGFR-TKI treatment
- Without communication barrier
- Do not exhibit signs of cognitive impairment that would prevent participation in an interview, as informally assessed during screening by the recruiter
- Physician:
- Provide informed consent
- Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals
- Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month
- Holding the title of associate chief physician or higher
- The following inclusion criteria must be met in order to be enrolled in the stage 2:
- Patient:
- Provide informed consent
- 18 years or older
- Diagnosed with stage IV NSCLC
- Currently receiving or previously received 1L EGFR-TKI treatment
- Without communication barrier
- Do not exhibit signs of cognitive impairment that would prevent participation in a survey, as informally assessed during screening by the recruiter
- Physician:
- Provide informed consent
- Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals
- Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month
- Holding the title of attending physician or higher
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Research Site Coordinator of this site? Confirm its status | Chengdu | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.